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Abstract
Background: There is evidence that the use of any psychotropic and the concomitant use of two or more 
benzodiazepines are related to an increased risk of fractures in old age. However, also controversial results exist. The 
aim was to describe associations between the use of a psychotropic drug, or the concomitant use of two or more of 
these drugs and the risk of fractures in a population aged 65 years or over.
Methods: This study was a part of a prospective longitudinal population-based study carried out in the municipality of 
Lieto, South-Western Finland. The objective was to describe gender-specific associations between the use of one 
psychotropic drug [benzodiazepine (BZD), antipsychotic (AP) or antidepressant (AD)] or the concomitant use of two or 
more psychotropic drugs and the risk of fractures in a population 65 years or over. Subjects were participants in the first 
wave of the Lieto study in 1990-1991, and they were followed up until the end of 1996. Information about fractures 
confirmed with radiology reports in 1,177 subjects (482 men and 695 women) during the follow-up was collected from 
medical records. Two follow-up periods (three and six years) were used, and previously found risk factors of fractures 
were adjusted as confounding factors separately for men and women. The Poisson regression model was used in the 
analyses.
Results: The concomitant use of two or more BZDs and the concomitant use of two or more APs were related to an 
increased risk of fractures during both follow-up periods after adjusting for confounding factors in men. No similar 
associations were found in women.
Conclusions: The concomitant use of several BZDs and that of several APs are associated with an increase in the risk of 
fractures in older men. Our findings show only risk relations. We cannot draw the conclusion that these drug 
combinations are causes of fractures.
Background
Fractures in old age create a major health problem with
considerable disability and mortality. Fractures are typi-
cally caused by a combination of a fall and an underlying
bone disease, e.g., osteoporosis [1]. Several risk factors
for falls and fractures have been identified, of which the
use of psychotropics, i.e., benzodiazepines (BZDs), anti-
depressants (ADs) or antipsychotics (APs), belongs to
avoidable ones [2]. The use of any psychotropic was
found to be a risk factor of fractures in a South-Korean
cohort study [3].
Large cohort studies have shown that the use of BZDs
increases the risk of fractures in the aged [4-6]. There are,
however, also controversial results [7]. In the majority of
case-control studies, positive relationships between BZD,
hypnotic or sedative use and the risk of fractures have
been found [8-10], while some studies present no such
findings [11]. Two surveys have revealed that the con-
comitant use of BZDs raises the risk of fractures up to
2.5-fold compared with the non-use [8,12].
According to case-control and cohort studies, the use
of ADs increases the risk of fractures in old age [13-16].
Cohort studies concerning the use of APs and the risk of
fractures are rare. Jacqmin-Gadda et al. (1998) did not
find a positive association between the use of APs and the
risk of fractures [15]. However, positive associations from
case-control studies exist [9,17,18].
The concomitant use of psychotropics is common in
the aged [19]. Despite this, associations between the con-
comitant use of psychotropics and the risk of fractures
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have not been studied in detail. The concomitant use may
create a stronger risk than the use of one psychotropic
alone [8]. According to our knowledge, our prospective
population-based epidemiological study is the first
cohort study to test the hypothesis about the associations
between the concomitant use of psychotropics and the
risk of fractures in the aged.
The aim was to describe associations between the use
of a benzodiazepine or a related drug (BZD), an antipsy-
chotic (AP), an antidepressant (AD), or the concomitant
use of two or more of these drugs and the risk of fractures
in a population aged 65 years or over.
Methods
Study population and examinations
This study was a part of a larger longitudinal, unselected,
population-based study carried out in the municipality of
Lieto, South-Western Finland [20]. The baseline data was
collected between October 1, 1990, and December 31,
1991, and the population consisted of all the residents in
Lieto born in 1926 or earlier (n = 1,283). Of these resi-
dents, 1,196 (93%), 488 men and 708 women, participated
in the baseline study.
The methods and variables used have been described in
detail in previous reports [20,21].
Data on fractures
Information about fractures confirmed with radiology
reports was collected individually from the medical
records from the baseline until the end of 1996. Data on
fractures were obtained for 1,177 participants (482 men
and 695 women) (98% of the baseline population), who
formed the subjects of this study [21].
Only the first fracture of each participant during the
follow-up period was included. Pathological fractures and
those caused by the most serious accidents were excluded
[20,21]. In the case of persons who sustained more than
one fracture in an accident, the main fracture contribut-
ing to the need for treatment was taken into account.
Fractures were classified using ICD-10 codes.
Medication data
Participants were asked to take their prescription forms,
medication lists and pill boxes to the examinations. Data
on the use of drugs were collected by a trained nurse by
interviewing and by checking the prescription forms,
medication lists, pill boxes and medical records of the
participants.
Drugs were defined by using the Anatomical Therapeu-
tic Chemical (ATC) Classification 2000 [22]. The groups
of drugs defined as those with effect on central nervous
system (CNS) and used in the analyses were as follows:
opioids (OPs) (ATC code N01AH, N02A, N02BE51,
R05DA, R05FA), antiepileptic drugs (AEs) (ATC code
N03A), anticholinergic drugs (ACHs) (ATC codes N04A,
N05AA01, N05AA02, N05AB01, N05AB02, N05AB03,
N05AB04, N05AC01, N05AC02, N05AF01, N05AF03,
N05AF05, N05BB01, N06AA04, N06AA06, N06AA09,
N06AA12, N02AG, A03AA, A03AB, A03AX03, A03B,
A03CA, A03CB31, A03DA, A03FA01, A04AD01,
A04AD12, C01BA01, C01BA03, C01BA51, C01BA71,
R03BB, M03B, G04BD, S01FA, R01BA01, R01BA51,
R06AB01, R06AE03, R06AE53), benzodiazepines and
related drugs (BZDs) (ATC codes N05BA, N05CD,
N03AE01, N05CF, A03CA, C01DA70, M05AA51,
N06CA01, N02BA71), antipsychotics (APs) (ATC codes
N05A, N06CA01) and antidepressants (ADs) (ATC codes
N06A, N06CA). Antipsychotics, antidepressants and
benzodiazepines together were classified as psychotropic
drugs.
Confounding variables
The selection of confounding variables was based on the
results of the previous study describing the predictors of
fractures within the same study population [21]. Accord-
ing to these results, high age, lowered handgrip strength
(<76 kPa), body mass index (BMI) under 30 kg/m2, and a
compression fracture in one or more upper lumbar or
thoracic vertebras are independent risk factors of frac-
tures in women, whereas high age, great number of
depressive symptoms, and a compression fracture in one
or more upper lumbar or thoracic vertebras were risk fac-
tors in men [21]. These predictors of fractures were used
as confounding variables in gender-specific analyses in
this study.
The weight (in light clothes) and height of the partici-
pants were measured in order to define body mass index
(BMI) [body mass (kg) divided by height (meters)
squared]. Depressive symptoms were assessed with the
Zung Self-rating Depression Scale (ZSDS). Handgrip
strength, as an indicator of muscle strength, was mea-
sured with an Elmed Vigorimeter® (hand dynamometer).
Chest X-rays were taken at baseline from two different
angles and were examined by the same experienced gen-
eral practitioner. A compressed fracture was diagnosed if
a vertebra was obviously compressed to a wedge shape.
Only definite compression fractures were recorded.
Statistical analyses
The differences in the use of drugs between men and
women were compared with chi-square test, or Fisher's
exact test. In order to describe associations between the
use of drugs and the risk of fractures, two follow-up peri-
ods (three and six years) were used. Subjects were fol-
lowed up from the baseline (October 1, 1990) to the
occurrence of the first fracture, and subjects with no frac-
tures were followed up to the end of the follow-up period
(December 31, 1993, or December 31, 1996) or to death.Nurminen et al. BMC Public Health 2010, 10:396
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The associations between a certain group of drugs or
combinations of drugs and fractures were analyzed at the
first phase using univariate and age-adjusted Poisson
regression analyses. Participants who did not use any psy-
chotropic or other drug affecting the central nervous sys-
tem (opioid, anticholinergic or antiepileptic medication)
were used as a control group. In the second phase, drugs
or combinations of drugs showing significant associa-
tions with fractures in age-adjusted analyses were
adjusted for confounding variables. Results were quanti-
fied using relative risks (RR) with their 95% confidence
intervals (CI). Analyses were done separately for men and
women. P-values less than 0.05 were considered statisti-
cally significant. Statistical analyses were carried out by
using SAS System for Windows version 9.1 (SAS Institute
Inc., Cary, NC).
Ethics approval and patient consent
Informed consent was obtained from all participants or
their caregivers. The baseline plan was approved by the
Joint Ethics Committee of the University of Turku and the
Turku University Central Hospital. Data collection for
follow-up was approved by the Finnish Ministry of Social
Affairs and Health, the Finnish National Research and
Development Centre for Welfare and Health, and the
Lieto District Health Authority.
Results
Participant characteristics
Nearly all participants lived in their own homes and were
able to walk independently (Table 1). On average, they
used 2.6 prescribed drugs regularly and 0.6 prescribed
drugs irregularly. The concomitant use of several psycho-
tropics was not common (Table 2).
Fractures and deaths
During the follow-up of three years (10/01/1990-12/31/
1993), 113 participants (9.6% of the baseline population),
29 men and 84 women, sustained 121 fractures (Table 3).
In the follow-up of six years (10/01/1990-12/31/1996),
178 participants (15.1% of the baseline population), 45
men and 133 women, sustained 221 fractures. Altogether,
160 participants died during the three-year follow-up
period, and 312 participants during six years.
Drugs and the risk of fractures
In univariate analyses, the use of two or more BZDs was
associated with an increased risk of fractures in men dur-
ing both follow-up periods (Table 4). These relationships
remained significant after adjusting for confounding vari-
ables. Poisson regression analysis adjusted for confound-
ing variables also showed the use of two or more APs to
be associated with an increased risk of fractures in men
during both follow-up periods.
Table 1: Participant characteristics, N = 1,177
No. (%)
Sex
Women 695 (59.0)
Men 482 (41.0)
Marital status
Married 649 (55.1)
Unmarried or divorced 131 (11.1)
Widowed 397 (33.7)
Place of living
Home, with other person(s) 749 (63.6)
Home, alone 364 (30.9)
Institution 64 (5.4)
Basic education
Less than basic 118 (10.0)
Basic 979 (83.2)
More than basic 80 (6.8)
Walking ability
Independently 956 (81.5)
Using a device 167 (14.2)
With help of other person(s) 50 (4.3)
Previous occupation
Service 205 (17.4)
Industry 421 (35.8)
Agriculture 453 (38.5)Nurminen et al. BMC Public Health 2010, 10:396
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In women, the use of two or more APs was related to an
increased risk of fractures in a univariate analysis in the
three-year follow-up, but this relationship did not remain
significant after adjusting for age (Table 5).
Discussion
Our results show that the concomitant use of two or
more BZDs and the concomitant use of two or more APs
are related to an increased risk of fractures in older men.
These findings were evident after adjusting for confound-
ing variables in the follow-up periods of either three or
six years.
Our study is a longitudinal prospective population-
based cohort study with accurate data about fractures
during the follow-up periods, use of drugs at baseline and
other baseline variables. These are the major method-
ological strengths. Many studies concerning associations
between the use of psychotropics and the risk of fractures
are based on a retrospective case-control setting that has
a limited ability to reveal causal relations [8,13,14,17]. We
were able to adjust our data for risk factors of fractures.
These confounding variables were found in the previous
study from the same data [21]. However, only risk rela-
tions can be estimated in an epidemiological prospective
follow-up study, and the associations found here do not
show causalities.
All fractures were confirmed by radiologists, and the
use of drugs was confirmed from prescription forms, pill
boxes and medical records to minimize recall bias.
Even though the numbers of fractures during the fol-
low-up periods (113 in three and 178 in six years) were
rather high, the number did not allow analyses by types of
fractures. The numbers of participants using a certain
drug or a combination of drugs were not high for every
drug. This possesses statistical limitations. Confidence
intervals tended to be wide, and there is a lack of statisti-
cal power in many Poisson regression model analyses.
In general, controlling confounding factors has posed
problems in many previous case-control studies [23,24].
Many previous studies have used administrative data-
bases, which do not contain the valuable information
about potential confounders [8,13]. The results of hospi-
tal-based case-control studies may be unreliable because
of possible control selection bias [24].
T h e  o n l y  m u s c l e  s t r e n g t h  t e s t  i n c l u d e d  i n  t h e  L i e t o
study was the handgrip strength test. The handgrip
strength was measured three times in a row with a hand
dynamometer. The average value of these three values
was calculated and recorded. The handgrip strength was
used as an overall muscle strength approximation
because of its feasibility in this population-based study.
There is evidence that handgrip strength reflects overall
muscle strength and self-rated health [25]. In addition,
lowered handgrip strength is an independent predictor of
hospitalization [26] and excess mortality [27]. Despite of
this, the use of specific muscle strength tests for lower
extremities may have given more reliable results concern-
ing participants' muscle strength of lower extremities.
All certain vertebral compression fractures found in
chest X-rays were recorded during the baseline data col-
lection. Routine chest X-rays were not performed during
the follow-up, but all vertebral compression fractures
diagnosed in clinical examinations during the follow-up
have been recorded (Table 3). Vertebral compression
fracture may not cause any clinical symptoms, or the
symptoms may be so mild that the patient does not take
contact with a doctor. Because of this, we may have
missed a group of undiagnosed vertebral compression
fractures. This must be taken into account when assess-
ing the results.
Our control group consisted of persons not using any
psychotropic, opioid, antiepileptic or anticholinergic
drugs. In addition to psychotropics, there is evidence that
opioids and antiepileptics may be related to a high risk of
falling and fractures [1,28]. Anticholinergic medications
can cause side-effects affecting the central nervous sys-
tem, and are related to the risk of cognitive decline [29],
and may, thus, raise the risk of falls. Our control group
was formed in order to compare the users of psychotro-
pic(s) with persons using no drug with known effects on
the central nervous system.
Another limitation is that the data on use of drugs was
collected only at baseline. It is possible that the use of
psychotropics changed during the follow-up periods at
least among some participants. The two cross-sectional
Family 98 (8.3)
Smoking
Current 94 (8.0)
Former 303 (25.8)
Mean ± SD
Age, yrs 73.2 ± 6.9
Body mass index, kg/m2 27.7 ± 4.9
Number of drugs
Regular 2.6 ± 2.5
Irregular 0.6 ± 1.0
Table 1: Participant characteristics, N = 1,177 (Continued)Nurminen et al. BMC Public Health 2010, 10:396
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studies in Lieto in 1990-1991 and 1998-1999 showed that
the proportions of users of psychotropics were similar in
both waves [30]. This finding supports the hypothesis of
the long term use of these drugs. We suggest that the use
of psychotropic drugs was long-lasting among many par-
ticipants.
Our results may be generalized to a population of 65
years or over living in a semi-industrialized municipality
[21]. Although the age of the participants has been lim-
ited to 65 years or over in the majority of previous stud-
ies, many surveys have also included younger participants
[10,31]. Therefore, the results of such studies are not
entirely comparable with those of ours. The subjects of
many previous cohort surveys have only comprised
women [7,32]. Many studies have focused on hip frac-
tures, and their results cannot be generalized to all frac-
tures [6,33].
One problem in comparing our results with the previ-
ous studies lies in the different definitions of drugs. Many
previous studies have used the definitions "hypnotics" or
"sedatives", but no exact descriptions about these groups
have been written [15,32]. In some surveys, specific drug
preparations, doses or both have been analyzed sepa-
rately, which was not an objective in this study.
Previous cohort studies that have found a positive asso-
ciation between the use of BZDs and the risk of foot frac-
tures have reported the risk ratio to be up to 1.72 [5].
Jacqmin-Gadda et al. (1998) found that the use of an anx-
iolytic creates a 2.25-fold risk for a hip fracture [15]. We
did not find a significant association between the use of
one BZD and the risk of fractures. The differences in
defining the fractures may partly explain the variation in
results.
The risk ratio between the concomitant use of two or
more BZDs and the risk of fractures has been found to be
2.10 [12]. A case-control study showed that the concomi-
tant use of two or more BZDs creates a 2.5-fold risk for
femur fracture [8]. We found the risk ratio for any kind of
fracture to be 4.9 in men using two or more BZDs. Our
results suggest that the concomitant use of several BZDs
increases the risk of fractures in men.
We did not find a positive association between the use
of one AD and the risk of fractures, whereas Spector et al.
(2007) found a 1.5-fold risk for the use of AD in a nursing
Table 2: Use and concomitant use of psychotropics at baseline among 1,177 participants
Drug Men (n = 482) Women (n = 695) P-valuea
No. (%) No. (%)
One BZD 76 (15.8) 187 (26.9) <.001
One AP 31 (6.4) 64 (9.2) .10
One AD 14 (2.9) 38 (5.5) .04
At least two BZDs 13 (2.7) 37 (5.3) .03
At least two APs 5 (1.0) 9 (1.3) .79
At least two ADs 1 (0.2) 0 (0.0) .41
BZD and APb 19 (3.9) 29 (4.2) .88
BZD and ADb 10 (2.1) 25 (3.6) .16
AP and ADb 5 (1.0) 13 (1.9) .34
At least one psychotropic 
drug
92 (19.1) 229 (32.9) <.001
a statistical difference between the sexes
b persons using concomitantly one drug or more drugs from each subgroup
BZD = benzodiazepine or related drug; AP = antipsychotic drug; AD = antidepressantNurminen et al. BMC Public Health 2010, 10:396
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home setting [16]. The difference in the setting may
explain the different results [16]. Ensrud et al. (2003)
found a significant association between the use of AD
and hip fractures in community-dwelling older women
[7]. The study was targeted to hip fractures in women,
which may partially explain the difference with our
results. No previous studies about the concomitant use of
ADs and the risk of fractures were found in our literature
search. The concomitant use of two ADs is rare in clinical
practice. It may lead to a potentially lethal serotonin syn-
drome, and should, thus, be avoided. No users of two or
more ADs were found in our material.
The use of two or more APs was found to be related to
an increased risk of fractures in men during both follow-
up periods. The relationship between the concomitant
use of APs and the risk of fractures has not been analyzed
in previous studies. The use of one AP has been found to
be associated with an increased risk of fractures in case-
control studies [17,18]. The only cohort study did not
show a positive association [15].
In our study, the results were similar for both follow-up
periods. The results indicate that the associations
between the concomitant use of BZDs or that of APs and
the risk of fractures remain constant during the years of
usage, assuming the drug use remained constant during
the follow-up years. According to a previous review, the
use of one BZD or that of one AP is associated with the
risk for falls in older populations [2]. The concomitant
use of several BZDs or APs may have more harmful
effects on postural balance than the use of only one drug.
Persons using several BZDs or APs may suffer more from
problems in postural balance or sedation caused by the
excessive use of drugs. These side-effects may increase
the risk for falls and fractures. Underlying diseases caus-
ing the concomitant use of these drugs may also have a
negative effect on physical functioning. Other underlying
factors, still undetectable, may exist as well, such as
straight negative effects of drugs on bone quality.
Why was the positive association found only in men?
More women used benzodiazepines and psychotropics
compared to men. Men and women used similar psycho-
tropic preparations in equal doses. Triazolam, oxazepam
and lorazepam were the most common BZDs in both
sexes. Levomepromazine and perphenazine were the
most common antipsychotics, and amitriptyline and dox-
epine the most common antidepressants in both men and
women. The differences between the sexes cannot be
explained by the types or doses of the psychotropics. One
explanation may be the greater tendency of women to fall
and to sustain fractures despite the use of psychotropics.
Other risk factors than the use of psychotropics, e.g. poor
muscle strengths, may play a greater role in women.
No man using two or more BZDs or APs used per oral
corticosteroids suggesting that the increase in fracture
risk in these groups was not due to use of per oral corti-
costeroid.
Table 3: Distribution of fracture types during the follow-up periods of three and six years among 1,177 participants taking 
into account the first fracture
Type of fracture Men (n = 482) Women (n = 695)
Three years Six years Three years Six years
No. (%) No. (%) No. (%) No. (%)
Total 29 (100) 45 (100) 84 (100) 133 (100)
Hip 6 (20.7) 8 (17.8) 17 (20.2) 29 (21.8)
Wrist 3 (10.3) 5 (11.1) 25 (29.8) 40 (30.1)
Tibial and ankle 7 (24.1) 9 (20.0) 10 (11.9) 12 (9.0)
Prox. humerus 1 (3.4) 2 (4.4) 10 (11.9) 15 (11.3)
Rib(s) 2 (6.9) 9 (20.0) 3 (3.6) 7 (5.3)
Vertebral compression 3 (10.3) 3 (6.7) 6 (7.1) 8 (6.0)
Other 7 (24.1) 9 (20.0) 13 (15.5) 22 (16.5)Nurminen et al. BMC Public Health 2010, 10:396
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Table 4: Relationships between use of psychotropics and risk of fractures in men
Drug Number of fracture cases 
No. (%)/controls No. (%)
Univariate analysis Age-adjusted analysis Adjusted analysisa
RR (95% CI) P-value RR (95% CI) P-value RR (95% CI) P-value
3-year follow-up
One BZD 7 (9.2)/20 (5.7) 1.7 (0.7-4.1) .21 1.4 (0.6-3.4) .44 - -
One AP 2 (6.5)/20 (5.7) 1.3 (0.3-5.4) .76 0.9 (0.2-4.1) .93 - -
One AD 1 (7.1)/20 (5.7) 1.3 (0.2-9.5) .81 1.0 (0.1-7.9) .97 - -
Two or more 
BZDs
3 (23.1)/20 (5.7) 4.9 (1.4-16.4) .01 4.7 (1.4-15.7) .01 4.7 (1.4-16.3) .01
Two or more APs 1 (20.0)/20 (5.7) 7.0 (0.9-52.0) .06 9.4 (1.2-71.1) .03 8.3 (1.0-66.2) .05
Two or more 
ADs
0 (0.0)/20 (5.7) - - - - - -
BZD and APb 2 (10.5)/20 (5.7) 2.3 (0.5 - 9.8) .27 2.5 (0.8-8.4) .13 - -
BZD and ADb 1 (10.0)/20 (5.7) 1.9 (0.3-14.2) .53 1.5 (0.2-11.3) .67 - -
AP and ADb 1 (20.0)/20 (5.7) 4.9 (0.7-36.6) .12 4.9 (0.7-36.0) .12 - -
6-year follow-up
One BZD 11 (14.5)/29 (8.3) 2.1 (1.1-4.3) .03 1.8 (0.9-3.7) .09 - -
One AP 4 (12.9)/29 (8.3) 2.0 (0.7-5.6) .20 1.6 (0.6-4.8) .37 - -
One AD 1 (7.1)/29 (8.3) 1.0 (0.1-7.1) .98 0.9 (0.1-6.6) .91 - -
Two or more 
BZDs
4 (30.8)/29 (8.3) 5.5 (1.9-15.8) .001 5.7 (2.0-16.2) .001 5.8 (2.0-16.6) .001
Two or more APs 1 (20.0)/29 (8.3) 6.2 (0.8-45.5) .07 7.6 (1.0-56.7) .05 7.9 (1.1-59.0) .04
Two or more 
ADs
0 (0.0)/29 (8.3) - - - - - -
BZD and APb 3 (15.8)/29 (8.3) 2.8 (0.7-9.3) .09 2.5 (0.8-8.4) .13 - -
BZD and ADb 1 (10.0)/29 (8.3) 1.6 (0.2-11.8) .64 1.5 (0.2-11.3) .67 - -
AP and ADb 1 (20.0)/29 (8.3) 4.8 (0.7-35.5) .12 4.9 (0.7-36.0) .12 - -
a adjusted for age, amount of depressive symptoms in Zung Self-rating Depression Scale and a compression fracture in one or more upper lumbar 
or thoracic vertebras at baseline
b persons using concomitantly one drug or more drugs from each subgroup
BZD = benzodiazepine derivative or related drug; AP = antipsychotic drug; AD = antidepressant; P-value = statistical significance; RR = relative 
risk; CI = confidence intervalNurminen et al. BMC Public Health 2010, 10:396
http://www.biomedcentral.com/1471-2458/10/396
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Table 5: Relationships between use of psychotropics and risk of fractures in women
Drug Number of fracture cases No. 
(%)/controls No. (%)
Univariate analysis Age-adjusted analysis Adjusted analysisa
RR (95% CI) P-value RR (95% CI) P Value RR (95% CI) P-value
3-year follow-up
One BZD 22 (11.8)/46 (11.9) 1.0 (0.6-1.7) .88 0.9 (0.5-1.5) .66 - -
One AP 9 (14.1)/46 (11.9) 1.3 (0.6-2.7) .47 1.1 (0.5-2.2) .83 - -
One AD 3 (7.9)/46 (11.9) 0.7 (0.2-2.2) .52 0.6 (0.2-1.9) .36 - -
Two or more 
BZDs
6 (16.2)/46 (11.9) 1.4 (0.6-3.4) .40 1.3 (0.5-3.0) .60 - -
Two or more 
APs
3 (33.3)/46 (11.9) 3.8 (1.2-12.2) .03 3.3 (1.0-10.7) .05 1.0 (0.1-7.0) .98
Two or more 
ADs
0 (0.0)/46 (11.9) - - - - - -
BZD and APb 5 (17.2)/46 (11.9) 1.7 (0.7-4.4) .24 1.4 (0.6-3.6) .46 - -
BZD and ADb 2 (8.0)/46 (11.9) 0.7 (0.2-2.9) .62 0.6 (0.1-2.5) .47 - -
AP and ADb 2 (15.4)/46 (11.9) 1.4 (0.3-5.7) .65 1.1 (0.3-4.7) .86 - -
6-year follow-up
One BZD 33 (17.7)/76 (19.6) 1.0 (0.6-1.5) .89 0.8 (0.6-1.3) .43 - -
One AP 13 (20.3)/76 (19.6) 1.2 (0.7-2.2) .54 1.0 (0.6-1.8) .98 - -
One AD 5 (13.2)/76 (19.6) 0.7 (0.3-1.8) .48 0.6 (0.2-1.5) .30 - -
Two or more 
BZDs
7 (18.9)/76 (19.6) 1.0 (0.5-2.2) .95 0.9 (0.4-2.0) .81 - -
Two or more 
APs
3 (33.3)/76 (19.6) 2.9 (0.9-9.2) .07 2.6 (0.8-8.3) .10 - -
Two or more 
ADs
0 (0.0)/76 (19.6) - - - - - -
BZD and APb 7 (24.1)/76 (19.6) 1.6 (0.8-3.6) .21 1.4 (0.6-3.0) .43 - -
BZD and ADb 3 (12.0)/76 (19.6) 0.7 (0.2-2.1) .48 0.6 (0.2-1.8) .34 - -
AP and ADb 4 (30.8)/76 (19.6) 1.9 (0.7-5.2) .21 1.6 (0.6-4.4) .38 - -
a Adjusted for age, hand grip strength, body mass index (BMI) and a compression fracture in one or more upper lumbar or thoracic vertebras at 
baseline
b Persons using concomitantly one drug or more drugs from each subgroup
BZD = benzodiazepine derivative or related drug; AP = antipsychotic; AD = antidepressant; P-value = statistical significance; RR = relative risk; 
CI = confidence intervalNurminen et al. BMC Public Health 2010, 10:396
http://www.biomedcentral.com/1471-2458/10/396
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Another explanation could be that the burden of
chronic diseases was heavier in men than in women. This
would suggest that at least a part of the identified
increase in fracture risk in men was associated with dis-
eases treated with psychotropics.
There is evidence that lower urinary tract symptoms
increase the risk of falls in older men [34]. However, also
urinary incontinence, that is common in women, has
been identified as one of the risk factors for falls [35].
These symptoms may increase the risk of falls by forcing
the participants to use the toilet at night time when they
are sleepy and the light may be poor. According to the lit-
erature, it is difficult to conclude if the symptoms of
benign prostate hyperplasia, for example, create a greater
r i s k  o f  f a l l i n g  i n  m e n  t h a n  t h e  s y m p t o m s  o f  u r i n a r y
incontinence in women.
Information concerning participants' alcohol intake
and bone mineral density did not belong to the baseline
variables. Finnish older men consume more alcohol than
women, but the consumption decreases with age [36].
There is, thus, a possibility that the concomitant use of
alcohol with two or more BZDs or APs has exposed men
to a fall (and a fracture). Osteoporosis is more common in
women than in men, but it is also known that diagnosing
and treating osteoporosis in men are inadequate [37].
Conclusions
The hypothesis, if there is a relationship between the con-
comitant use of several psychotropic drugs and the risk of
fracture, has not been studied previously. We tested this
hypothesis, and our results show that the concomitant
use of two or more BZDs and the concomitant use of two
or more APs are related to an increased risk of fractures
in older men. These findings were evident after adjusting
for confounding variables. Our findings show only risk
relations. We cannot draw the conclusion that these drug
combinations are causes of fractures.
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